Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin

Pitavastatin, a novel potent 3-hydroxymethylglutaryl coenzyme A reductase inhibitor, is distributed selectively to the liver and excreted into bile in unchanged form in rats. We reported previously that the hepatic uptake is mainly mediated by organic anion transporting polypeptide (OATP) 1B1, whereas the biliary excretion mechanism remains to be clarified. In the present study, we investigated the role of breast cancer resistance protein (BCRP) in the biliary excretion of pitavastatin. The ATP-dependent uptake of pitavastatin by human and mouse BCRP-expressing membrane vesicles was significantly higher compared with that by control vesicles with Km values of 5.73 and 4.77 μM, respectively. The biliary excretion clearance of pitavastatin in Bcrp1(-/-) mice was decreased to one-tenth of that in control mice. The biliary excretion of pitavastatin was unchanged between control and Eisai hyperbilirubinemic rats, indicating a minor contribution of multidrug resistance-associated protein (Mrp) 2. This observation differs radically from that for a more hydrophilic statin, pravastatin, of which biliary excretion is largely mediated by Mrp2. These data suggest that the biliary clearance of pitavastatin can be largely accounted for by BCRP in mice. In the case of humans, transcellular transport of pitavastatin was determined in the Madin-Darby canine kidney II cells expressing OATP1B1 and human canalicular efflux transporters. A significant basal-to-apical transport of pitavastatin was observed in OATP1B1/MDR1 and OATP1B1/MRP2 double transfectants as well as OATP1B1/BCRP double transfectants, implying the involvement of multiple transporters in the biliary excretion of pitavastatin in humans. This is in contrast to a previous belief that the biliary excretion of statins is mediated mainly by MRP2.

[1]  K. Kajinami,et al.  Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. , 2006, Cardiovascular drug reviews.

[2]  K. Maeda,et al.  Identification of the Hepatic Efflux Transporters of Organic Anions Using Double-Transfected Madin-Darby Canine Kidney II Cells Expressing Human Organic Anion-Transporting Polypeptide 1B1 (OATP1B1)/Multidrug Resistance-Associated Protein 2, OATP1B1/Multidrug Resistance 1, and OATP1B1/Breast Cancer R , 2005, Journal of Pharmacology and Experimental Therapeutics.

[3]  K. Maeda,et al.  Bile Salt Export Pump (BSEP/ABCB11) Can Transport a Nonbile Acid Substrate, Pravastatin , 2005, Journal of Pharmacology and Experimental Therapeutics.

[4]  A. V. van Herwaarden,et al.  Sex-Dependent Expression and Activity of the ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (BCRP/ABCG2) in Liver , 2005, Molecular Pharmacology.

[5]  A. V. van Herwaarden,et al.  The Breast Cancer Resistance Protein (BCRP/ABCG2) Affects Pharmacokinetics, Hepatobiliary Excretion, and Milk Secretion of the Antibiotic Nitrofurantoin , 2005, Molecular Pharmacology.

[6]  Yuichi Sugiyama,et al.  Lack of Improvement of Oral Absorption of ME3277 by Prodrug Formation Is Ascribed to the Intestinal Efflux Mediated by Breast Cancer Resistant Protein (BCRP/ABCG2) , 2005, Pharmaceutical Research.

[7]  Yuichi Sugiyama,et al.  Role of Breast Cancer Resistance Protein (Bcrp1/Abcg2) in the Extrusion of Glucuronide and Sulfate Conjugates from Enterocytes to Intestinal Lumen , 2005, Molecular Pharmacology.

[8]  M. Oshimura,et al.  FUNCTIONAL ASSESSMENT OF ABCG2 (BCRP) GENE POLYMORPHISMS TO PROTEIN EXPRESSION IN HUMAN PLACENTA , 2005, Drug Metabolism and Disposition.

[9]  Y. Sugiyama,et al.  Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). , 2004, Pharmacogenetics.

[10]  Y. Sugiyama,et al.  Functional Analysis of SNPs Variants of BCRP/ABCG2 , 2004, Pharmaceutical Research.

[11]  K. Maeda,et al.  Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans , 2004, Journal of Pharmacology and Experimental Therapeutics.

[12]  P. G. Wells,et al.  Antisense Evidence for Nuclear Factor-κB–Dependent Embryopathies Initiated by Phenytoin-Enhanced Oxidative Stress , 2004 .

[13]  H. Kusuhara,et al.  Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[14]  Sharon Marsh,et al.  Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype , 2004, Clinical pharmacology and therapeutics.

[15]  Kim L. R. Brouwer,et al.  The Complexities of Hepatic Drug Transport: Current Knowledge and Emerging Concepts , 2004, Pharmaceutical Research.

[16]  L. Doyle,et al.  Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) , 2003, Oncogene.

[17]  Jos H Beijnen,et al.  The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. , 2003, Cancer research.

[18]  A. Sánchez Navarro,et al.  Clinical pharmacokinetics of statins. , 2003, Methods and findings in experimental and clinical pharmacology.

[19]  Yuichi Sugiyama,et al.  ABCG2 Transports Sulfated Conjugates of Steroids and Xenobiotics* , 2003, Journal of Biological Chemistry.

[20]  Yuichi Sugiyama,et al.  Polymorphisms of OATP‐C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics , 2003, Clinical pharmacology and therapeutics.

[21]  H. Fujino,et al.  Interaction between Several Medicines and Statins , 2003, Arzneimittelforschung.

[22]  J. Schellens,et al.  Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Y. Miki,et al.  C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. , 2002, Molecular cancer therapeutics.

[24]  T. Abe,et al.  Transcellular Transport of Organic Anions Across a Double-transfected Madin-Darby Canine Kidney II Cell Monolayer Expressing Both Human Organic Anion-transporting Polypeptide (OATP2/SLC21A6) and Multidrug Resistance-associated Protein 2 (MRP2/ABCC2)* , 2002, The Journal of Biological Chemistry.

[25]  J. Kojima,et al.  Effect of Biliary Excretion on the Pharmacokinetics of Pitavastatin (NK-104) in Dogs , 2001 .

[26]  M. Vijver,et al.  Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. , 2001, Cancer research.

[27]  J. Schellens,et al.  Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. , 2000, Journal of the National Cancer Institute.

[28]  Y. Sugiyama,et al.  Characterization of inducible nature of MRP3 in rat liver. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[29]  G R Wilkinson,et al.  OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[30]  Hiroshi Suzuki,et al.  Characterization of the Transport Properties of Cloned Rat Multidrug Resistance-associated Protein 3 (MRP3)* , 1999, The Journal of Biological Chemistry.

[31]  Vincenzo,et al.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. , 1998, Cancer research.

[32]  H. Fujino,et al.  Studies on the Metabolic Fate of NK-104, a New Inhibitor of HMG-CoA Reductase (1) : Absorption, Distribution, Metabolism and Excretion in Rats , 1998 .

[33]  E. Stein,et al.  Comparison of statins in hypertriglyceridemia. , 1998, The American journal of cardiology.

[34]  Y. Sugiyama,et al.  Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[35]  P. Borst,et al.  Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Y. Sugiyama,et al.  Kinetic analysis of hepatobiliary transport of organic anions in Eisai hyperbilirubinemic mutant rats. , 1993, The Journal of pharmacology and experimental therapeutics.

[37]  Y. Sugiyama,et al.  Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. , 2004, Molecular pharmacology.

[38]  E. Schuetz,et al.  Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. , 2003, Pharmacogenetics.

[39]  H. Fujino,et al.  Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase--effect of cMOAT deficiency on hepatobiliary excretion in rats and of mdr1a/b gene disruption on tissue distribution in mice. , 2002, Drug metabolism and pharmacokinetics.

[40]  T Nakagawa,et al.  A pharmacokinetic analysis program (multi) for microcomputer. , 1981, Journal of pharmacobio-dynamics.